A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

NCT02889367 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Odalasvir 100 mg
DRUG: Placebo
DRUG: Odalasvir 500 mg
DRUG: Odalasvir (Up to maximum 1000 mg)

Sponsor

Janssen Research & Development, LLC